MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of “Moderate Buy” by Analysts

MDxHealth SA (NASDAQ:MDXH) has earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $7.75.

A number of brokerages have recently issued reports on MDXH. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and set a $7.00 target price on shares of MDxHealth in a research note on Tuesday, December 23rd.

Hedge Funds Weigh In On MDxHealth

Large investors have recently made changes to their positions in the business. Intesa Sanpaolo Wealth Management bought a new position in shares of MDxHealth in the fourth quarter worth about $36,000. GSA Capital Partners LLP bought a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Lido Advisors LLC bought a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth in the 3rd quarter worth approximately $53,000. Finally, Squarepoint Ops LLC purchased a new position in MDxHealth in the 4th quarter worth approximately $51,000.

MDxHealth Trading Down 9.1%

Shares of NASDAQ:MDXH opened at $2.90 on Wednesday. The stock has a 50 day moving average of $3.50 and a 200 day moving average of $3.76. The company has a market cap of $143.55 million, a PE ratio of -4.33 and a beta of 1.61. MDxHealth has a 12-month low of $1.36 and a 12-month high of $5.33.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Thursday, February 26th. The company reported $999.00 EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $999.13. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The company had revenue of $29.55 million for the quarter, compared to analysts’ expectations of $26.05 million. Equities research analysts predict that MDxHealth will post -1.15 earnings per share for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.